Centus Gets European Bevacizumab Approval

Equidacent Rival To Avastin Gains Marketing Authorization

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Centus Biotherapeutics has received formal European Commission approval for its Equidacent biosimilar rival to Avastin.

Thumbs_Up_EU
Centus has received formal European Commission approval for bevacizumab • Source: Shutterstock

Centus Biotherapeutics, the joint venture between Fujifilm Kyowa Kirin Biologics and AstraZeneca, has received formal European Commission approval for its Equidacent (bevacizumab) biosimilar version of Roche’s Avastin. The biosimilar received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in July. (Also see "EMA’s CHMP Is Set To Adopt Position On Another Avastin Biosimilar" - Generics Bulletin, 20 July, 2020.)

Commenting on the pan-European marketing authorization, Kyowa Kirin Biologics president and CEO Atsushi Matsumoto said the firm was “proud that...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.